| Literature DB >> 30742650 |
Alfonso Wolfango Avolio1,2, Rita Gaspari2,3, Luciana Teofili2,4, Giuseppe Bianco1, Giorgia Spinazzola3, Paolo Maurizio Soave3, Gianfranco Paiano3, Alessandra Gioia Francesconi3, Andrea Arcangeli2,3, Nicola Nicolotti5, Massimo Antonelli2,3.
Abstract
BACKGROUND: Postoperative respiratory failure (PRF, namely mechanical ventilation >48 hours) significantly affects morbidity and mortality in liver transplantation (LTx). Previous studies analyzed only one or two categories of PRF risk factors (preoperative, intraoperative or postoperative ones). The aims of this study were to identify PRF predictors, to assess the length of stay (LoS) in ICU and the 90-day survival according to the PRF in LTx patients.Entities:
Mesh:
Year: 2019 PMID: 30742650 PMCID: PMC6370207 DOI: 10.1371/journal.pone.0211678
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Dual-perspective approach to potential risk factors.
| Potential risk factors | |
| | Age at transplant; Sex; BMI; Indication; Diabetes; MELD at transplant; MELDNa at transplant; Hemofiltration; Left Ventricular Ejection Fraction percentage; Systolic pulmonary artery pressure; Diastolic dysfunction; pH; PaO2 and PaCO2 at listing; Restrictive or Obstructive pattern at Pulmonary Function Tests; Encephalopathy grade; Hepatopulmonary syndrome; Portopulmonary syndrome |
| | VVBP; Porto-caval anastomosis; transfusion requirements (Packet red blood cells, Fresh frozen plasma, Platelets); Operation time |
| | D-MELD; BAR; CIT |
| | Donor age; Standard donor/non-standard donor [ |
| | Hemofiltration or Hemodialysis; SAPS II; Mechanical Ventilation; PaO2; PaCO2; PaO2/FiO2 ratio; Post-operative Pulmonary Complications |
| | MEAF; MELD at the 3rdpod; RIFLE at the 3rdpod (2–3 versus 0–1); creatinine at the 3rdpod |
| | Age at transplant; Sex; BMI; Diabetes; SAPS II |
| | Indication; MELD at listing; MELD at transplant; MELDNa at listing; MELDNa at transplant; Hepatopulmonary syndrome; Portopulmonary syndrome; VVBP; Transfusion requirements (Packet red blood cells, Fresh frozen plasma, Platelets) |
| | Donor Age; Standard donor/non-standard donor [ |
| | Hemofiltration; RIFLE at the 3rdpod; creatinine at the 3rdpod |
| | Left Ventricular Ejection Fraction percentage; Systolic Pulmonary Artery Pressure; Diastolic dysfunction |
| | Encephalopathy grade |
| | Mechanical Ventilation; pH, PaO2, and PaCO2 at listing; pre-extubation PaO2, PaCO2 and PaO2/FiO2ratio; post-extubation PaO2, PaCO2 and PaO2/FiO2ratio; Restrictive or Obstructive pattern at Pulmonary Function Tests; Post-operative Pulmonary Complications |
BMI: body mass index, MELD: Model for End-stage Liver Disease, PaO2: partial pressure of arterial oxygen, PaCO2: partial pressure of arterial CO2, VVBP: Veno-Venous Bypass, D-MELD: Donor Model for End-stage Liver Disease, BAR: BAlance of Risk score, CIT: Cold Ischemia Time, ICU: Intensive Care Unit, SAPS: Simplified Acute Physiology Score, FiO2: Fraction of Inspired Oxygen, MEAF: Model for Early Allograft Function, RIFLE: Risk Injury Failure Loss End-stage of kidney disease
Characteristics of the study population and comparison between PRF and no-PRF cases (univariate analysis).
| Factors | All (n = 200) | PRF (n = 72) | no-PRF (n = 128) | ||
|---|---|---|---|---|---|
| Age (years) | 56 (48–62) | 56 (48–62) | 56 (48–62) | ||
| | |||||
| BMI | 25.6 ± 3.9 | 25.3 ± 3.9 | 25.8 ± 3.9 | ||
| HCC | 75 (37.5) | 28 (38.9) | 47 (36.7) | ||
| | |||||
| | 13 (11–18) | ||||
| | 21 (16–27) | ||||
| | |||||
| MELDNa in HCC pts | 16 (12–21) | 19 (14–23) | 15 (11–20) | ||
| | |||||
| | |||||
| | |||||
| | |||||
| | |||||
| | |||||
| Obstructive pattern | 14 (7.0) | 6 (8.3) | 8 (6.3) | ||
| | |||||
| | |||||
| Porto-caval anastomosis | 10 (5.0) | 6 (8.3) | 4 (3.1) | ||
| | |||||
| | |||||
| Fresh Frozen Plasma (units) | 16.8 ± 16.6 | 18.8 ± 17.7 | 15.5 ± 15.7 | ||
| | |||||
| | |||||
| D-MELD at LTx | 985 ± 529 | 1131 ± 586 | 903 ± 477 | ||
| BAR | 6.8 ± 4.3 | 8.1 ± 4.8 | 6.1 ± 3.7 | ||
| | |||||
| Age (years) | 55 (38–67) | 56 (43–68) | 55 (38–66) | ||
| Non-standard donor | 82 (41.0) | 34 (47.2) | 48 (37.5) | ||
| Extended criteria donor | 94 (47.0) | 37 (51.4) | 57 (44.5) | ||
| | |||||
| PaO2 pre-extubation (mmHg) | 147.8 ± 35.8 | 144.2 ± 31.5 | 149.0 ± 39.0 | ||
| | |||||
| PaO2/FiO2 pre-extubation | 369 ± 104 | 352 ± 87 | 380± 111 | ||
| | |||||
| | |||||
| | |||||
| | |||||
| | |||||
| | |||||
| | |||||
| | |||||
| | |||||
| | |||||
| | |||||
| | |||||
| | |||||
| | |||||
| | 49 (24.5) | 15 (20.8) | 34 (26.6) | ||
| | 37 (18.5) | 15 (20.8) | 22 (17.2) | ||
| | 13 (6.5) | 7 (9.7) | 6 (4.7) | ||
| | 12 (6.0) | 7 (9.7) | 5 (3.9) | ||
| | |||||
| | |||||
| | |||||
PRF: Postoperative Respiratory Failure, IQR: interquatile range, BMI: body mass index, LTx: Liver Transplantation, HCC: Hepatocellular carcinoma, MELD: Model for End-stage Liver Disease, LVEF%: Left Ventricular Ejection Fraction percentage, SPAP: Systolic Pulmonary Arterial Pressure, PPS: porto-pulmonary syndrome, PaO2: partial pressure of arterial oxygen, PaCO2: partial pressure of arterial CO2, TLC: Total Lung Capacity, FEV1: Forced Expiratory Flow in 1 second, FVC: Forced Vital Capacity, VVBP: Veno-Venous bypass, D-MELD: Donor Model for End-stage Liver Disease, BAR: BAlance of Risk score, CIT: Cold Ischemia Time, ICU: Intensive Care Unit, SAPS: Simplified Acute Physiology Score, FiO2: Fraction of Inspired Oxygen, MEAF: Model for Early Allograft Function, RIFLE: Risk Injury Failure Loss End-stage of kidney disease
Fig 1Frequencies of MELD in no-HCC and HCC patients.
(A) Histograms of MELD according to the outcome (PRF vs no-PRF) are reported. For each subset mean ± SD and median (IQR) are reported. (B) Frequencies and (percentages) are reported in PRF and no-PRF patients according to MELD ≥22 and MELD <22.
Fig 2ROC curve analysis.
The Areas Under the Curve and Standard Errors are reported under each subset.
Characteristics of PRF patients according to extubation and weaning failure (univariate analysis).
| Factors | Extubation failure (n = 28) | Weaning failure (n = 44) | |
|---|---|---|---|
| Age (years) | 58 (50–62) | 54 (47–62) | |
| Female sex | 8 (28.6) | 14 (31.8) | |
| BMI >30 | 2 (7.1) | 9 (20.5) | |
| HCC | 11 (39.3) | 17 (38.6) | |
| MELD at LTx | 20 (14–26) | 23 (15–31) | |
| | |||
| Encephalopathy grade ≥2 | 2 (7.1) | 2 (4.5) | |
| Restrictive pattern | 7 (25.0) | 14 (31.8) | |
| Obstructive pattern | 3 (10.7) | 3 (6.8) | |
| Portal Vein thrombosis | 2 (7.1) | 7 (15.9) | |
| | |||
| Packed red blood cell (units) | 11.3 ± 9.9 | 14.1 ± 11.3 | |
| Packed red blood cell >10 units | 12 (42.9) | 28 (63.6) | |
| Fresh Frozen Plasma (units) | 14.5 ± 14.8 | 22.0 ± 19.1 | |
| Platelets (units) | 1.60 ± 1.80 | 1.75 ± 1.43 | |
| Operation time (hours) | 12 (12–14) | 13 (12–14) | |
| D-MELD at LTx | 1067 ± 556 | 1172 ± 606 | |
| BAR | 7.1 ± 4.0 | 8.8 ± 5.3 | |
| CIT (hours) | 8 (7–8) | 8 (7–9) | |
| SAPS II at the ICU admission | 37.8 ± 13.3 | 41.6 ± 16.9 | |
| PaCO2 pre-extubation (mmHg) | 37.4 ± 5.6 | 38.0 ± 6.1 | |
| PaO2/FiO2 pre-extubation | 372 ± 88 | 337 ± 85 | |
| MEAF | 5.3 ± 2.0 | 5.9 ± 1.9 | |
| MEAF 8 & over | 3 (10.7) | 9 (20.5) | |
| MELD on 3rd p.o.d. (mg/dl) | 17.6 ± 6.2 | 18.9 ± 8.4 | |
| Bilirubin on 3rd p.o.d. (mg/dl) | 5.7 ± 4.3 | 8.0 ± 5.6 | |
| Creatinine on 3rd p.o.d. (mg/dl) | 1.32 ± 0.57 | 1.58 ± 0.73 | |
| | |||
| | 39.2 ± 7.8 | 39.3 ± 6.1 | |
| | |||
| | |||
| | 17 (60.7) | 36 (81.8) | |
| | 7 (25.0) | 13 (29.5) | |
| | |||
| | 9 (7–15) | 10 (7–18) | |
| | |||
PRF: Postoperative Respiratory Failure, BMI: body mass index, HCC: Hepatocellular carcinoma, MELD: Model for End-stage Liver Disease, LTx: Liver Transplantation, VVBP: Veno-Venous bypass, D-MELD: Donor Model for End-stage Liver Disease, BAR: BAlance of Risk score, CIT: Cold Ischemia Time, ICU: Intensive Care Unit, SAPS: Simplified Acute Physiology Score, PaO2: partial pressure of arterial oxygen, PaCO2: partial pressure of arterial CO2, FiO2: Fraction of Inspired Oxygen, MEAF: Model for Early Allograft Function, RIFLE: Risk Injury Failure Loss End-stage of kidney disease, LoS: Length of stay.
Fig 3Survival analysis according with the PRF status.
Patient survival at 90 days was 97.6%±1.4% in the no-PRF group (continuous line), 96.4%±3.5% in the EF subgroup (dash-interrupted line), and 79.2%±6.2% in the WF subgroup (dot-interrupted line). Survival was significantly different between PRF and no-PRF groups (p<0.001) and, within PRF patients, between EF and WF- subgroups (p = 0.047). WF, but not EF patient’ survival, differed from that of no-PRF patients.